Schering AG/Berlex ends Levulan marketing
Executive Summary
Schering AG returns Levulan Kerastick marketing and development rights to Dusa as of June 6; Berlex' marketing responsibilities for the photodynamic non-hyperkeratotic actinic keratoses therapy will be dissolved during a 12-month transition period. Sales since launch in September 2000 have totaled $921,000...